PureTech Health plc (NASDAQ:PRTC - Get Free Report) saw strong trading volume on Monday . 16,106 shares changed hands during trading, an increase of 303% from the previous session's volume of 3,999 shares.The stock last traded at $22.26 and had previously closed at $20.85.
Analysts Set New Price Targets
Several equities research analysts have weighed in on the company. Leerink Partnrs upgraded PureTech Health to a "strong-buy" rating in a report on Monday, September 9th. Leerink Partners initiated coverage on shares of PureTech Health in a report on Monday, September 9th. They issued an "outperform" rating and a $45.00 price target on the stock.
Get Our Latest Research Report on PRTC
PureTech Health Trading Up 7.9 %
The business has a fifty day simple moving average of $20.34 and a two-hundred day simple moving average of $23.68.
Institutional Trading of PureTech Health
A hedge fund recently bought a new stake in PureTech Health stock. Birch Hill Investment Advisors LLC acquired a new stake in shares of PureTech Health plc (NASDAQ:PRTC - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 302,000 shares of the company's stock, valued at approximately $7,550,000. Birch Hill Investment Advisors LLC owned about 1.26% of PureTech Health at the end of the most recent quarter. 0.04% of the stock is currently owned by hedge funds and other institutional investors.
About PureTech Health
(
Get Free Report)
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider PureTech Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.
While PureTech Health currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
